abrdn plc Has $2.14 Million Stake in NewAmsterdam Pharma (NASDAQ:NAMS)

abrdn plc lifted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 69.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 129,060 shares of the company’s stock after purchasing an additional 53,060 shares during the period. abrdn plc’s holdings in NewAmsterdam Pharma were worth $2,142,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in NAMS. Jennison Associates LLC bought a new stake in shares of NewAmsterdam Pharma in the 1st quarter valued at about $22,015,000. Artal Group S.A. bought a new position in NewAmsterdam Pharma during the 1st quarter worth approximately $18,920,000. Janus Henderson Group PLC acquired a new position in shares of NewAmsterdam Pharma in the 1st quarter worth approximately $15,018,000. Decheng Capital LLC bought a new stake in NewAmsterdam Pharma during the second quarter valued at $7,684,000. Finally, TimesSquare Capital Management LLC acquired a new stake in NewAmsterdam Pharma during the 1st quarter worth about $5,407,000. Institutional investors own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

NAMS has been the topic of several recent analyst reports. Needham & Company LLC initiated coverage on NewAmsterdam Pharma in a research note on Wednesday, August 28th. They issued a “buy” rating and a $36.00 price target on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $33.80.

NewAmsterdam Pharma Stock Performance

NAMS opened at $18.03 on Tuesday. The firm has a 50-day moving average of $17.23 and a 200 day moving average of $18.45. NewAmsterdam Pharma has a fifty-two week low of $8.64 and a fifty-two week high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.08. The business had revenue of $2.28 million during the quarter, compared to the consensus estimate of $2.20 million. On average, equities analysts forecast that NewAmsterdam Pharma will post -2.06 earnings per share for the current fiscal year.

Insider Activity

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 19.50% of the stock is owned by company insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.